VTGN - VistaGen Therapeutics EPS misses by $0.01 beats on revenue November, 10 2021 04:28 PM VistaGen Therapeutics Inc. VistaGen Therapeutics (NASDAQ:VTGN): Q2 GAAP EPS of -$0.07 misses by $0.01. Revenue of $0.36M (+9.1% Y/Y) beats by $0.1M. Press Release For further details see: VistaGen Therapeutics EPS misses by $0.01, beats on revenue